P
Priavoid develops orally available all‑D‑peptide therapeutics that target and reverse disease‑specific protein aggregation in neurodegenerative disorders. Its proprietary detangler platform delivers non‑immunogenic compounds that cross the blood‑brain barrier and act inside affected neurons. The pipeline includes Phase 2 Alzheimer’s candidate PRI‑002 and programs for Parkinson’s, tauopathies, and ALS.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Priavoid develops orally available all‑D‑peptide therapeutics that target and reverse disease‑specific protein aggregation in neurodegenerative disorders. Its proprietary detangler platform delivers non‑immunogenic compounds that cross the blood‑brain barrier and act inside affected neurons. The pipeline includes Phase 2 Alzheimer’s candidate PRI‑002 and programs for Parkinson’s, tauopathies, and ALS.